Artiva Biotherapeutics (ARTV) News Today $1.96 -0.09 (-4.39%) Closing price 04:00 PM EasternExtended Trading$1.99 +0.03 (+1.53%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of "Buy" by BrokeragesMay 29 at 2:47 AM | americanbankingnews.comArtiva Biotherapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28 at 4:05 PM | globenewswire.comArtiva Biotherapeutics (NASDAQ:ARTV) and Bio-Techne (NASDAQ:TECH) Financial SurveyMay 24, 2025 | americanbankingnews.comLatest Artiva Biotherapeutics Stock News | NASDAQ:ARTV | BenzingaMay 22, 2025 | benzinga.comTD Cowen Keeps Their Buy Rating on Artiva Biotherapeutics, Inc. (ARTV)May 16, 2025 | theglobeandmail.comNeedham Remains a Buy on Artiva Biotherapeutics, Inc. (ARTV)May 16, 2025 | theglobeandmail.comResearch Analysts Issue Forecasts for ARTV FY2025 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now anticipates thatMay 16, 2025 | marketbeat.comArtiva reports promising AlloNK therapy results in B-NHL studyMay 15, 2025 | investing.comArtiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingMay 13, 2025 | globenewswire.comQ1 Earnings Estimate for ARTV Issued By WedbushArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Wedbush issued their Q1 2026 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a note issued to investors on Thursday, May 8th. Wedbush analyst D. Nierengarten expects that the company will post earnings per shareMay 13, 2025 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPSArtiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.15).May 12, 2025 | marketbeat.comArtiva Biotherapeutics Reports Q1 2025 ProgressMay 11, 2025 | tipranks.comArtiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy RatingMay 8, 2025 | tipranks.comArtiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA ClearanceMay 8, 2025 | tipranks.comArtiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business HighlightsMay 8, 2025 | globenewswire.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Buy" by BrokeragesArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has received an average recommendation of "Buy" from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month pricMay 6, 2025 | marketbeat.comArtiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual MeetingApril 28, 2025 | globenewswire.comArtiva Biotherapeutics (NASDAQ:ARTV) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday.April 10, 2025 | marketbeat.comArtiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeedsApril 9, 2025 | markets.businessinsider.comArtiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical OfficerApril 8, 2025 | globenewswire.comArtiva Biotherapeutics Reports 2024 Financial ResultsApril 2, 2025 | tipranks.comArtiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comEquities Analysts Set Expectations for ARTV Q1 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for Artiva Biotherapeutics in a report released on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will earn ($0.68) per shaMarch 29, 2025 | marketbeat.comArtiva Biotherapeutics stock rises following analyst optimismMarch 29, 2025 | uk.investing.comBrokers Offer Predictions for ARTV FY2025 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now anticipatesMarch 28, 2025 | marketbeat.comAnalysts Issue Forecasts for ARTV Q1 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush issued their Q1 2025 earnings per share estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Monday, March 24th. Wedbush analyst D. Nierengarten forecasts that the company will pMarch 28, 2025 | marketbeat.comCantor Fitzgerald Sticks to Their Buy Rating for Artiva Biotherapeutics, Inc. (ARTV)March 27, 2025 | markets.businessinsider.comArtiva Biotherapeutics price target lowered to $20 from $23 at Cantor FitzgeraldMarch 27, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV)HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday.March 27, 2025 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor FitzgeraldCantor Fitzgerald decreased their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Tuesday.March 26, 2025 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Earns Outperform Rating from WedbushWedbush reaffirmed an "outperform" rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday.March 26, 2025 | marketbeat.comArtiva Biotherapeutics' (ARTV) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday.March 26, 2025 | marketbeat.comArtiva Biotherapeutics Reports Full Year 2024 Results and Updates on AlloNK® Autoimmune Program with Key Leadership StrengtheningMarch 26, 2025 | nasdaq.comArtiva Biotherapeutics, Inc. (ARTV) Gets a Buy from TD CowenMarch 25, 2025 | markets.businessinsider.comArtiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business HighlightsMarch 24, 2025 | globenewswire.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have been given an average rating of "Buy" by the six research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The averagMarch 15, 2025 | marketbeat.comArtiva Biotherapeutics (ARTV) Expected to Announce Earnings on TuesdayArtiva Biotherapeutics (NASDAQ:ARTV) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comArtiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 20, 2025 | globenewswire.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Buy" from BrokeragesArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Buy" by the six brokerages that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokFebruary 18, 2025 | marketbeat.comArtiva Biotherapeutics expands board with industry veteranJanuary 30, 2025 | msn.comArtiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.January 29, 2025 | globenewswire.comArtiva Biotherapeutics, Inc.'s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV)Artiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of Artiva Biotherapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.January 8, 2025 | marketbeat.comGeode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Geode Capital Management LLC acquired a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 308,930 shares of the company'sJanuary 6, 2025 | marketbeat.comState Street Corp Acquires Shares of 86,559 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)State Street Corp bought a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 86,559 shares of the company's stock, valued at approximately $1,337,000. StateJanuary 3, 2025 | marketbeat.comResearch Analysts Issue Forecasts for ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - HC Wainwright issued their FY2024 EPS estimates for Artiva Biotherapeutics in a note issued to investors on Monday, December 30th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($6.00) for theJanuary 1, 2025 | marketbeat.comArtiva Biotherapeutics initiated with a Buy at H.C. WainwrightDecember 31, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Artiva Biotherapeutics (ARTV) with Buy RecommendationDecember 31, 2024 | msn.comArtiva Biotherapeutics (NASDAQ:ARTV) Now Covered by HC WainwrightHC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a research note on Monday. They set a "buy" rating and a $20.00 target price for the company.December 30, 2024 | marketbeat.comFranklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Franklin Resources Inc. acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 520,301 shares of the company's stock, valued at approxiDecember 23, 2024 | marketbeat.comWellington Management Group LLP Invests $2.91 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Wellington Management Group LLP bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 194,108 shares of the compaDecember 18, 2024 | marketbeat.com Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTV Media Mentions By Week ARTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTV News Sentiment▼0.470.87▲Average Medical News Sentiment ARTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTV Articles This Week▼41▲ARTV Articles Average Week Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRGX News SLS News INBX News TLSA News OGI News ELDN News KOD News CTMX News NBTX News PRQR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTV) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARTV Stock Free ARTV Stock Alerts